EPI-005

EPI-005 is a preclinical-stage monoclonal antibody developed by Epibiotech (EPI) for the treatment of alopecia areata (AA). It functions by neutralizing C-X-C motif chemokine ligand 12 (CXCL12), also known as stromal cell-derived factor 1 (SDF-1). CXCL12 is a chemokine that plays a critical role in the recruitment and activation of inflammatory cells, including T lymphocytes, to the hair follicle environment. By blocking the interaction of CXCL12 with its receptors, EPI-005 aims to mitigate the autoimmune-mediated destruction of hair follicles that characterizes alopecia areata, potentially allowing for hair regrowth. The asset is currently in the early discovery and preclinical development phase.

Other names

CXCL12 Neutralizing AntibodyCXCL-12 Neutralizing AntibodyCXCL 12 Neutralizing Antibody